Foundation for the National Institute of Health Inc

“The Compensation Committee of the Board reviewed and concurred with the CEO's decisions establishing and adjusting the senior executive team's annual salaries and related compensation decisions. The Compensation Committee also approved the compensation level of the CEO and related compensation decisions. This process is undertaken annually.”

“The Board has an Executive Committee, which can make decisions on behalf of the Board (with some exceptions) between board meetings.”

“The Form 990 is prepared and reviewed by an independent accounting firm. Prior to the submission of the Foundation for NIH's Form 990 to the Internal Revenue Service, each voting member of the board of directors shall be provided with a copy of the draft Form 990 as approved by the Chief Financial Officer.”

“Directors, officers and employees are required to annually sign a statement which affirms that they have: - Received a copy of the conflict of interest policy - Read, understood and agreed to comply with the policy - Received and reviewed a listing of corporate and foundation donors, contractors, vendors, grantees, principal investigators and financial institutions with whom the FNIH has a current relationship - No actual or apparent conflicts of interest other than those disclosed in the statement. They must also make certain notifications in particular circumstances. The conflict of interest policy also has mechanisms for handling such conflicts.”

“All such documents are available upon request. In addition, the governing documents and financial statements are available on the FNIH website.”

“To create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization.”

“PROGRAM ONE - RESEARCH PROGRAMS - ACCELERATING MEDICINES PARTNERSHIP PROGRAM The FNIH manages the Accelerating Medicines Partnership (AMP) program with the interests of the collective scientific and medical research communities in mind. Its mission is to improve understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate new and effective therapies to patients. All AMP projects operate under the broad principle of delivering pre-competitive advancements to the research and medical fields and enabling the broadest possible access and use of AMP research discoveries. A critical component of each public-private partnership in the AMP program is an agreement among partners to make data and analyses arising from the collaboration publicly accessible to benefit the broader biomedical community. Individual AMP projects frequently establish public portals to rapidly disseminate data from their research efforts, and AMP-funded publications are required to be made available publicly within specific timeframes. At the center of the AMP program is a common goal of accelerating new and effective therapies to patients. AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes. The AMP program celebrated its 10-year anniversary in 2024 with a two-day symposium spotlighting the wide-ranging impact of the initiative. BIOMARKERS CONSORTIUM The Biomarkers Consortium (BC) creates and leads cross-sector efforts that validate and qualify biomarkers and other tools to accelerate better decision making for the development of new therapeutics and health technologies. It convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogate endpoints. The BC is helping facilitate, catalyze, and support a new era of precision medicine by advancing biomarker science to enable earlier interventions, personalized treatments, and better outcomes in disease prevention, detection, diagnosis, and therapy. GENECONVENE GLOBAL COLLABORATIVE The GeneConvene Global Collaborative continues to advance best practices and support informed decision-making on the scientific, regulatory, and policy questions raised by the development of genetic biocontrol technologies to control the spread of malaria and other mosquito-borne diseases. GeneConvene convened in 2024 a working group of developers preparing for field trials to assess technologies for entomological monitoring and surveillance, hosting a webinar and meeting on environmental monitoring, and leading a Gene Drive Research Forum discussion of the opportunities for ecological modeling to further contribute to safety assessments. Through the African Genetic Biocontrol Consortium, the program also conducted two workshops for scientists and science communicators to build relationships and skills. GeneConvene also strengthened biosafety regulatory capacity through a training conducted with the African Union Development Agency-NEPAD and sponsored a course for 50 faculty and PhD-level scientists from African institutions on genome editing. RESEARCH PROGRAMS FOR ACCELERATING NEW THERAPIES RESEARCHING COVID TO ENHANCE RECOVERY-TREATING LONG COVID (RECOVER-TLC) RECOVER-TLC is a partnership between the NIH's National Institute of Allergy and Infectious Diseases and the FNIH, with the overarching goal to launch additional Long COVID clinical trials with promising agents. Therapeutic submissions were submitted to the online portal in 2024, and a process was created to enable uniform assessment of all submitted agents. These”

“RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH A-PLUS: ANTIBIOTIC PROVES COST EFFECTIVE IN REDUCING MATERNAL INFECTIONS A 2023 international trial, supported in part by the FNIH, revealed that one dose of the oral antibiotic azithromycin during labor can greatly reduce maternal sepsis or death in low- and middle-income countries. For this work, the research team won top honors from the Clinical Research Forum in 2024. Two analyses published in 2024 using data from that trial, the Azithromycin Prevention in Labor Use Study (A-PLUS), assessed possible additional benefits of this strategy to prevent infections, which account for approximately 11% of maternal deaths worldwide. One of the two recent studies showed that any maternal infection, including sepsis, abscesses, and wound infections, occurred 29% less often when the drug was administered during labor. The second study, which modeled the benefits and costs of intrapartum azithromycin, showed a reduction in hospital readmissions, unplanned clinical visits, and use of additional antibiotics. Using the average health-care costs across the study's eight clinical sites, the savings was estimated at $32,661 per 100,000 pregnancies. STRENGTHENING THE PATIENT VOICE Patients are at the heart of the FNIH mission, and their voices are incorporated into our research programs. People with lived experiences, patient advocacy groups, and care providers are vital to our work, helping to ensure that our programs look holistically at the impact our research will have on health and well-being. The FNIH's patient engagement strategy - including the Patient Ambassadors and Patient Engagement Council - reflects our commitment to ensuring patient voices guide our work. Their insights are essential to shaping impactful, forward-looking research programs.”

“PROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - POWERING SCIENCE: 2024 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCES The Lurie Prize recognized outstanding achievement by promising scientists aged 52 years old or younger. The award included a $100,000 honorarium. PAUL-GALLIN TRAILBLAZER PRIZE FOR PHYSICIAN-SCIENTISTS The Paul-Gallin Trailblazer Prize recognizes the outstanding contributions of early- to mid-career physician-scientists whose research translates basic discoveries into novel approaches for diagnosing, preventing, treating, or curing disease and disability. The award includes a $100,000 honorarium. CHARLES A. SANDERS, MD, PARTNERSHIP AWARD We recognize our partners and their contributions through the annual Charles A. Sanders, MD, Partnership Award. This prize recognizes persons and/or organizations that have made significant contributions to our work in creating, implementing, and nurturing public-private partnerships that build bridges to breakthroughs in improved therapeutics, diagnostics, and potential cures. KOVLER PRIZE FOR TRUST IN LIFE SCIENCE JOURNALISM The Kovler Prize, which debuted in 2024 and carries a $25,000 honorarium, recognizes individual reporters who make complex health- and science-related topics digestible for the public. EVENTS AND EDUCATION In collaboration with the NIH and generous donors and partners, the FNIH manages training initiatives that offer educational opportunities to science students, ranging from high school to post-doctoral scholars, crossing boundaries and cultures. They learn through intensive training, collaborative engagement, mentoring, and hands-on research. Legacy funds from individual benefactors and foundations help move scientific achievement farther, faster, and give hope to future patients. Individual programs provide financial support, mentoring, and recognition to promising young scientists. Here is a just a sample of how the FNIH and its supporters power science: - The Deeda Blair Research Initiative for Disorders of the Brain awarded in 2024 three promising early-career physician-scientists with bold approaches to address mental illness. Each awardee received $200,000. This initiative was established by Mrs. William McCormick Blair, Jr., a member of the FNIH Board of Directors. - The Medical Research Scholars Program is a one-year intensive training program on the NIH campus offering medical, dental, and veterinary students opportunities to become engaged in research early in their careers. The FNIH has supported a total of 572 scholars since the program was established. - The FNIH promotes emerging research from up-and-coming scientists through annual lectures co-sponsored by the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the National Institute of Allergy and Infectious Diseases, the National Center for Complementary and Integrative Health, and elsewhere. - For a complete list of all the ways the FNIH is powering science, go to the FNIH website.”

“Approximately $122 Million of FNIH's Cash and Investments are invested in high quality short-term fixed income securities which are committed to FNIH's restricted assets.”

“Refund of Prior Year Grants - 654801; Total - 654801;”